Newsroom
Keep up with the latest
Featured
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
Media Center
Press Release
Scribe Therapeutics Raises $100M Series B Financing to Further Develop 'CRISPR by Design' Platform and Pipeline of Breakthrough Genetic Medicines
March 31, 2021
Read Now
Press Release
Scribe Therapeutics Raises $100M Series B Financing to Further Develop 'CRISPR by Design' Platform and Pipeline of Breakthrough Genetic Medicines
March 31, 2021
Read Now
Media
Doudna’s Scribe Rewrites CRISPR Drug Development with $100 Million Series B
March 31, 2021
Genetic Engineering & Biotechnology News
Read Now
Press Release
Doudna’s Scribe Rewrites CRISPR Drug Development with $100 Million Series B
March 31, 2021
Genetic Engineering & Biotechnology News
Read Now
Media
Scribe closes $100M series B round for gene editing rewrite
March 31, 2021
BioWorld
Read Now
Press Release
Scribe closes $100M series B round for gene editing rewrite
March 31, 2021
BioWorld
Read Now
Media
Scribe Therapeutics Closes Series B Round With $100M To Target Gene Editing
March 31, 2021
Crunchbase News
Read Now
Press Release
Scribe Therapeutics Closes Series B Round With $100M To Target Gene Editing
March 31, 2021
Crunchbase News
Read Now